Repligen (NASDAQ:RGEN) Hits New 1-Year High at $299.57

Shares of Repligen Co. (NASDAQ:RGEN) reached a new 52-week high during trading on Wednesday . The stock traded as high as $299.57 and last traded at $299.57, with a volume of 2370 shares changing hands. The stock had previously closed at $294.50.

RGEN has been the topic of a number of recent analyst reports. Stephens raised their price target on shares of Repligen from $255.00 to $290.00 and gave the stock an “overweight” rating in a report on Friday, August 20th. Craig Hallum lifted their target price on shares of Repligen from $251.00 to $258.00 and gave the stock a “buy” rating in a report on Wednesday, July 28th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Repligen presently has a consensus rating of “Buy” and an average price target of $247.60.

The firm’s 50-day moving average is $249.07 and its 200-day moving average is $213.73. The company has a market capitalization of $16.31 billion, a P/E ratio of 164.53 and a beta of 0.90.

Repligen (NASDAQ:RGEN) last announced its earnings results on Monday, July 26th. The biotechnology company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.27. The company had revenue of $162.96 million during the quarter, compared to analyst estimates of $144.24 million. Repligen had a net margin of 19.65% and a return on equity of 9.21%. The firm’s quarterly revenue was up 86.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.42 earnings per share. Sell-side analysts expect that Repligen Co. will post 2.76 earnings per share for the current fiscal year.

In other news, CEO Anthony Hunt sold 25,000 shares of the stock in a transaction on Thursday, September 9th. The shares were sold at an average price of $294.75, for a total value of $7,368,750.00. Following the sale, the chief executive officer now owns 214,495 shares of the company’s stock, valued at $63,222,401.25. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Karen A. Dawes sold 4,585 shares of the stock in a transaction on Tuesday, July 20th. The shares were sold at an average price of $202.09, for a total transaction of $926,582.65. The disclosure for this sale can be found here. Insiders sold 51,880 shares of company stock worth $14,064,053 in the last three months. Insiders own 1.20% of the company’s stock.

Institutional investors have recently modified their holdings of the business. RPg Family Wealth Advisory LLC bought a new position in Repligen during the 2nd quarter worth about $27,000. Creative Financial Designs Inc. ADV lifted its position in shares of Repligen by 50.0% during the second quarter. Creative Financial Designs Inc. ADV now owns 150 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 50 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Repligen during the second quarter valued at about $37,000. Institutional & Family Asset Management LLC lifted its position in shares of Repligen by 1,900.0% during the first quarter. Institutional & Family Asset Management LLC now owns 200 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 190 shares during the last quarter. Finally, Signaturefd LLC raised its position in shares of Repligen by 67.5% in the 1st quarter. Signaturefd LLC now owns 206 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 83 shares during the last quarter. Institutional investors own 83.82% of the company’s stock.

Repligen Company Profile (NASDAQ:RGEN)

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Featured Article: Quick Ratio

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.